Many leading pharma and biotechs have invested in messenger RNA (mRNA) technology to develop COVID-19 vaccines and are now exploring their potential in other disease areas (Figure 1). The success ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

RNA therapeutics promise rapid, personalized and flexible treatments against multiple diseases. In this article, we will ...

The veterinary vaccines market is experiencing robust growth driven by factors such as the rising prevalence of zoonotic ...

A new mRNA therapy tested in mice may target the root cause of the potentially fatal pregnancy disorder preeclampsia. It's ...

LNPs have gained solid ground as a drug delivery system for mRNA due to their success in the vaccines arena.

After decades of disappointment, efforts to create jabs that can stimulate the immune system to fight cancer are showing renewed promise ...

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

Cancer vaccine research seems to be having a moment. Are recent advances a leap forward or is it too soon to tell?

Other key elements of the agreement include the development of a second-generation saRNA (self-amplifying RNA) for vaccines to be used in Latin America “and beyond.” Additionally, the partners ...

It’s also the first-ever clinical stage trial for a CRISPR-Cas13 RNA editing therapy, marking a significant milestone for the field of research. While it’s early days for the technology ...